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Integrated safety profile of atacicept: an analysis of
pooled data from the atacicept clinical trial
programme
Caroline Gordon1, Roberto Bassi2, Peter Chang2, Amy Kao2, David Jayne3,
David Wofsy4 and Patricia Fleuranceau-Morel2
Abstract
Objective. To characterize the overall safety profile of atacicept, we conducted an integrated analysis
of pooled safety data from all 17 clinical studies to date.
Methods. Three data sets were used to investigate safety endpoints: a double-blind placebo-con-
trolled set (n¼ 1568), an SLE set (n¼ 761) and a full analysis set (n¼ 1845; including all 17 studies).
Results. Of 1568 patients in the double-blind placebo-controlled-set, 30.8% received placebo, and 8.2,
24.5 and 36.5% received atacicept 25, 75 and 150mg, respectively. Treatment-emergent adverse event
(TEAE) rates (adjusted by treatment-exposure) were generally higher with atacicept vs placebo, but no
consistent association was found between atacicept dose and specific TEAEs or mortality. Serious infec-
tion and serious TEAE rates were similar for atacicept and placebo. The TEAE-related discontinuation
rates were higher with atacicept vs placebo (16.1 vs 10.9/100 patient-years). In the full analysis set, 11
deaths occurred during treatment. Across indications, exposure-adjusted mortality rates/100 patient-years
(95% CI) were 3.60 (0.90, 14.38), 0.34 (0.05, 2.43) and 1.18 (0.49, 2.82) with atacicept 25, 75 and
150mg, respectively, and 0.44 (0.06, 3.12) with placebo. In SLE patients, exposure-adjusted mortality
rates were 1.45 (0.54, 3.87) with atacicept 150mg and 0.78 (0.29, 2.07) across all atacicept-treated
patients. No deaths occurred with atacicept 75mg or placebo. In the SLE and double-blind placebo-con-
trolled sets, pharmacodynamic effects of atacicept were not associated with increased infection rates.
Conclusion. The results of this integrated safety analysis support further development and evaluation
of atacicept in selected patients for whom potential benefits might outweigh risks.
Key words: atacicept, autoimmune diseases, safety, B-cell targeting, clinical trials, systemic lupus erythema-
tosus, adverse events
Introduction
Atacicept is a fully human, soluble fusion protein con-
sisting of a transmembrane activator and calcium modu-
lating cyclophilin ligand (CAML) interactor extracellular
ligand-binding domain and a modified Fc-IgG1 domain
[1], which has been shown to bind and neutralize the
cytokines B lymphocyte stimulator (BLyS) and a
proliferation-inducing ligand (APRIL) in vitro [2]. BLyS
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and APRIL are key modulators of B-cell activity [3–6], and
their levels have been shown to be elevated alongside
dysregulated B-cell activity in various autoimmune con-
ditions, including SLE [7, 8].
In in vitro studies and preclinical animal models, dual
inhibition of BLyS and APRIL by atacicept was more po-
tent than blocking of BLyS alone, resulting in decreased
levels of autoreactive B cells, plasma cells and Ig [9–11].
Vigolo et al. [12] recently demonstrated that atacicept
binding is not negatively affected by the loop region of
the BLyS 60-mer (a naturally occurring cleaved human
BLyS), which was shown temporarily to prevent binding
of the anti-BLyS antibody, belimumab. Consistent with
these data, atacicept reduces serum Ig levels in a dose-
dependent manner in humans [13–15].
Atacicept has been investigated clinically in healthy
volunteers [16, 17], patients with B-cell malignancies,
such as chronic lymphocytic leukaemia, non-Hodgkin’s
lymphoma, multiple myeloma and Waldenstro¨m’s mac-
roglobulinaemia [18–20], and patients with autoimmune
conditions, including RA [21–24], multiple sclerosis (MS)
[25], LN [26], optic neuritis (ON) [27] and, most recently,
SLE [14, 15, 28]; a study in IgA nephropathy is currently
ongoing (NCT02808429).
Although the primary endpoints in two large SLE studies
[APRIL-SLE (Phase II/III; NCT00624338) and ADDRESS II
(Phase IIb; NCT01972568)] were not met, post hoc analy-
ses suggested that weekly treatment with s.c. atacicept
150mg had beneficial effects on disease activity and re-
sponse rates, particularly in ADDRESS II, in patients with
high disease activity (HDA; SLEDAI-2K  10) at screening
[14, 15]. In APRIL-SLE, atacicept 150mg reduced disease
flare rates and prolonged the time to a new flare vs pla-
cebo [14]. However, two infection-related deaths in this
group prompted early cessation of enrolment within the
150mg dose arm. In ADDRESS II, a greater proportion of
HDA patients treated with atacicept had SLE responder
index [SRI]-4 and SRI-6 responses and a reduced risk for
severe flare (as assessed by BILAG index A manifestation
and by the Safety of oestrogens in Lupus Erythematosus
National Assessment [SELENA]-SLEDAI flare index) com-
pared with placebo-treated patients [15]. In both studies,
the frequency of serious treatment-emergent adverse
events (TEAEs; including infections) was comparable be-
tween atacicept and placebo groups [14, 15].
Safety findings, including unexpected decreases in
IgG levels (APRIL-LN), serious infections (APRIL-LN and
APRIL-SLE) including two cases of pneumonia with fatal
outcome (APRIL-SLE), myocardial infarction with fatal
outcome (Study 014 in LN) and increase of disease ac-
tivity (ATAMS in MS and ATON in ON) [14, 25–27] were
observed in earlier studies of atacicept in autoimmune
diseases; these studies were partly (APRIL-SLE; ataci-
cept 150mg arm) or fully terminated as a consequence.
After these observations, risk mitigation measures were
implemented for the ADDRESS II study in SLE, its long-
term extension and other subsequent studies. These
measures included medical monitor reviews of patient
screening data to confirm eligibility and up-to-date
vaccinations against pneumococcus and seasonal influ-
enza. It is worth noting that infection rates were lower in
the ADDRESS II study and its extension than those ob-
served in APRIL-SLE, and no study-drug-related deaths
were reported [15, 28].
Given the observed benefit of atacicept, particularly in
SLE patients with HDA, and the observed safety profile of
atacicept in the ADDRESS II study and its long-term ex-
tension, there is rationale for further characterization of the
overall safety profile of atacicept. This will serve as a foun-
dation for future studies to explore the efficacy of ataci-
cept further in specific subsets of patients, in whom the
benefits might outweigh the potential risks. Therefore, we
conducted an integrated analysis of safety data from all
atacicept clinical studies to date to characterize the overall
safety profile of atacicept. Specifically, we sought to inves-
tigate adverse event (AE) and infection rates with atacicept
vs placebo in double-blind placebo-controlled (DBPC) tri-
als, and mortality rates across all atacicept studies.
Methods
Studies included in the analysis
Data from 17 clinical studies of atacicept were included in
this integrated analysis (Fig. 1). Twelve studies were con-
ducted in patients with autoimmune diseases (SLE [14, 15,
28–30], LN [26], RA [21–24], MS [25] and ON [27]), three
studies focused on patients with B-cell malignancies
(chronic lymphocytic leukaemia, non-Hodgkin’s lymphoma,
multiple myeloma and Waldenstro¨m’s macroglobulinaemia)
[18–20], and two were conducted in healthy volunteers
[16, 17]. All studies have been described previously and
are summarized in Supplementary Table S1, available at
Rheumatology Advances in Practice online. Briefly, in the
DBPC Phase II and Phase II/III studies, atacicept was ad-
ministered s.c. weekly at doses of 25, 75 or 150mg, and
patients received concomitant standard-of-care therapies
as appropriate. Study protocols were in accordance with
the Declaration of Helsinki and were approved by the ap-
propriate institutional review boards or ethics committees;
written informed consent was provided by all patients.
Data sets
Analyses were based on three separate pooled data sets
to analyse all AEs (safety data) from all patients in the
data set who were exposed to placebo or atacicept dur-
ing the studies: (i) DBPC set, comprising safety data from
eight atacicept Phase II or II/III DBPC studies conducted
to date [not including long-term extension studies (LTEs)]
[14, 15, 21–23, 25–27]; (ii) full analysis (FA) set, compris-
ing safety data from all 17 clinical studies with atacicept,
including those belonging to the DBPC set [14–30]; and
(iii) SLE set, comprising safety data from the APRIL-SLE
and ADDRESS II studies [14, 15, 28].
Endpoints and assessments
Key safety endpoints analysed in the DBPC set included
the overall incidence of AEs of special interest (AESI),
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TEAEs, serious AEs and TEAEs leading to treatment dis-
continuation. Pre-defined AESI categories were based on
potential or theoretical risks and included infections, hyper-
sensitivity and injection site reactions (ISRs), severe hypo-
gammaglobulinaemia (IgG <3g/l), cardiac events (cardiac
arrhythmias, cardiac failure and ischaemic heart disorders),
embolic and thromboembolic events, vestibular disorders,
demyelinating disorders, malignant tumours, and depres-
sion and suicide ideation (Supplementary Appendix 1,
available at Rheumatology Advances in Practice online). In
the FA set, the overall number and causes of deaths and
the exposure-adjusted mortality rates across the atacicept
clinical trial programme were examined. In the SLE set,
the association between changes from baseline in IgG lev-
els and mature B-cell numbers and rates of serious and/or
severe infection were assessed.
Statistical analysis
Analyses were performed using descriptive statistics for
continuous variables or by using the frequency count and
percentage for categorical data. The TEAEs, AESIs and
mortality rates were adjusted by atacicept exposure. The
exposure-adjusted incidence rate (EAIR) in each treat-
ment arm was defined as the ratio of the number of
patients with an event to the sum of the duration of expo-
sure to treatment of the patients up to the time of the first
event or the end of observation (whichever occurred first)
and was expressed as the rate per 100 patient-years. In
patients with SLE, serious infections [defined by The
International Council for Harmonisation of Technical
Requirements for Pharmaceuticals for Human Use (ICH)
as resulting in death or life-threatening] and/or severe
infections [defined by the Common Terminology Criteria
for Adverse Events as a significant impairment of function
(Qualitative Toxicity Scale)] were analysed (as a combined
term) per quartile of changes from baseline in the serum
IgG levels and mature B-cell numbers.
Results
Study population (DBPC, FA and SLE sets)
The DBPC set included 1568 patients treated for a total
of 841.4 patient-years (Table 1; SLE, 48.5%; LN, 0.4%;
FIG. 1 Study population
*Patients treated with adalimumab (n¼79) were not included in this analysis; †Extensions were not included within the
DBPC set. RA studies: 25 072 [24], AUGUST I [21], AUGUST II [22], AUGUST III [23]. MS studies: ATAMS and ATAMS
EXT [25]. ON sudy: ATON [27]. SLE studies: 25 842 [30], 25 050 [29], APRIL-SLE [14], ADDRESS II and ADDRESS II
LTE [15]. LN studies: EMR700461-014 (not published); APRIL-LN [26]. Studies in malignancies: 25 899 [19];
25 335þ25 336 EXT [20]; B-cell neoplasms [18]. Studies in healthy subjects: 24 675 [16, 17]; EMR700461-022 [17].
CLL: chronic lymphocytic leukaemia; DPBC: double-blind placebo-controlled; EXT: extension; LTE: long-term exten-
sion; MM: multiple myeloma; MS: multiple sclerosis; NHL: non-Hodgkin’s lymphoma; ON: optic neuritis; PBO: pla-
cebo; WM, Waldenstro¨m’s macroglobulinaemia.
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RA, 32.7%; MS, 16.2%; and ON, 2.2%). Of these, 483
patients (30.8%) received placebo, and 129 (8.2%), 384
(24.5%) and 572 (36.5%) received atacicept 25, 75 and
150mg, respectively. Baseline demographics were bal-
anced across treatment arms within the same indication
(Table 1) [14, 15, 21–23, 25–28]. The FA set included
safety data from 1845 patients, including healthy volun-
teers (n¼75) [16, 17], patients enrolled in Phase I stud-
ies (B-cell malignancies, n¼55; and autoimmune
diseases, n¼ 147) [18–20, 24, 29, 30] and patients in the
LTEs of DBPC studies [25, 28]. The SLE set included
761 patients enrolled in Phase II/III studies; these
patients were treated for a total of 652.4 patient-years.
The treatment duration ranged from 24 to 52weeks in
the DBPC and SLE sets and from 4 to 260weeks in the
FA set (Supplementary Table S1, available at
Rheumatology Advances in Practice online).
Exposure-adjusted incidence of AESIs and TEAEs
(DBPC set)
Treatment exposure was similar between the placebo
and atacicept 75 and 150mg groups (278.25, 225.02
and 286.67 patient-years, respectively), but was lower in
the atacicept 25mg group (51.48 patient-years)
(Table 2). Treatment exposure was highest in patients
with SLE and lowest in those with ON and LN
(Supplementary Table S2, available at Rheumatology
Advances in Practice online).
Exposure-adjusted rates of AESI were assessed by
treatment/dose (Table 2) and indication (Supplementary
Table S2, available at Rheumatology Advances in Practice
online). Infections were the most common treatment-
emergent AESIs, and the EAIRs were generally higher with
atacicept than with placebo (128.65 vs 107.78 per 100
patient-years). However, EAIRs of serious and severe
infections were low across all patients (7.93 and 4.29 per
100 patient-years, respectively), with no notable differen-
ces between atacicept and placebo. Although the overall
infection rates were highest with atacicept 150mg, serious
and severe infection rates were comparable to those with
atacicept 75mg. There was no notable increase in the
rates of serious and severe infections with atacicept vs
placebo in patients with SLE, RA or ON. In patients with
LN or MS, the numbers of serious and severe infections
were higher with atacicept than with placebo, but few
patients presented with these events. Herpes zoster infec-
tions occurred infrequently overall [n¼42 (5.07 per 100
patient-years)], and rates were similar between atacicept
and placebo. These infections were most frequent in SLE
patients (n¼ 20) and occurred at slightly lower rates in RA
and MS patients.
Hypersensitivity reactions occurred more frequently
with atacicept vs placebo (19.40 vs 13.92 per 100
patient-years) but were mostly mild in severity.
Hypersensitivity reactions were most frequent in patients
with ON or LN and were similar among patients with
MS, RA or SLE. One patient with SLE in the atacicept
75mg group was hospitalized for anaphylactic shock af-
ter a bee sting; however, the causality was determinedT
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to be unrelated to atacicept. Rates of ISRs were higher
with atacicept compared with placebo, with the highest in-
cidence in the atacicept 150mg group. However, ISRs
were mostly of mild (n¼117, 15.4%) or moderate (n¼25,
3.3%) intensity, with three severe ISRs (0.4%). The EAIRs
of ISRs were highest in patients with MS, LN and ON.
Severe hypogammaglobulinaemia (IgG <3g/l) was in-
frequent across all treatment groups, occurring in two
(0.5%) and four (0.7%) patients in the atacicept 75 and
150mg groups, respectively, and being limited to
patients with SLE (0.4%), LN (75.0%) or MS (0.5%). All
patients with LN received loading doses of MMF ( 1g/
day) and high-dose CSs (prednisone, up to 60mg/day)
before the administration of atacicept.
The EAIRs of cardiac arrhythmias, cardiac failure and
ischaemic heart disorders were higher with atacicept vs pla-
cebo. The highest incidence of cardiac arrhythmias was
seen in the atacicept 25mg group, and no evidence of an
atacicept dose effect was observed. The highest EAIR of
cardiac failure was observed in the atacicept 150mg group
(5.28 per 100 patient-years), and EAIRs of 3.90, 3.13 and
2.17 per 100 patient-years were observed with atacicept 25
and 75mg and placebo, respectively. Analysis of these data
by disease indication showed that cardiac arrhythmia rates
were higher with atacicept than with placebo in patients
with MS or RA, but were similar between atacicept and pla-
cebo in SLE patients. Ischaemic heart disorders were most
common with atacicept 25 (5.91 per 100 patient-years) and
75mg (5.92 per 100 patient-years) in the overall DBPC set
and were more frequent with atacicept vs placebo in
patients with RA (4.80 vs 1.62 per 100 patient-years).
Embolic and thromboembolic events were more frequently
reported in placebo-treated patients vs atacicept-treated
patients (3.96 vs 2.85 per 100 patient-years), with the differ-
ence being most pronounced in patients with LN or MS.
The incidence of vestibular disorders was 8.94 vs 7.01
per 100 patient-years with atacicept (all doses) vs pla-
cebo, without evidence of an atacicept dose effect.
Seven out of 1568 patients experienced a demyelination
event, with a higher incidence being observed with ata-
cicept than with placebo (1.07 vs 0.36 per 100 patient-
years). Demyelination was observed only in patients with
MS or ON and in a single patient with RA, for whom the
demyelination event was unconfirmed.
Malignant or unspecified tumours were reported in a total
of five (0.32%) atacicept-treated patients across the SLE
(n¼ 2), RA (n¼ 2) and MS (n¼1) groups, and no cases
were observed with placebo; of note, the study sample in-
cluded considerably more atacicept-treated than placebo-
treated patients for these indications, and the overall expo-
sure [sum of the duration of treatment of the patients (pla-
cebo or atacicept) until first AE or end of observation] was
lower in the placebo group (Supplementary Table 2, avail-
able at Rheumatology Advances in Practice online).
The EAIRs of depression were higher with placebo than
with atacicept (5.08 vs 3.93 per 100 patient-years); no cases
of suicide ideation or suicidal behaviour were observed.
Serious TEAE rates were low overall and similar be-
tween atacicept and placebo groups. In atacicept-treated
patients, the highest EAIRs were observed in the 25mg
group and the lowest in the 150mg group (30.02 and
21.79 per 100 patient-years, respectively); however, these
results should be viewed with caution owing to the smaller
number of patients and lower exposure in the 25mg
group. Rates of severe TEAEs were higher with atacicept
than with placebo but were similar across atacicept dose
groups (Table 2). Analysis of TEAEs by disease indication
showed that serious TEAE rates were higher with atacicept
than with placebo only in patients with LN, RA and ON,
and severe TEAEs were more commonly observed with
atacicept than with placebo in all five indications.
Discontinuation of treatment owing to TEAEs was relatively
infrequent, but was more common with atacicept vs pla-
cebo (16.07 vs 10.85 per 100 patient-years) overall, with
the highest rate being seen with atacicept 25mg (27.57
per 100 patient-years) owing to the relatively smaller expo-
sure time in this treatment arm (Table 2). Unadjusted dis-
continuation rates owing to TEAEs with atacicept were
10.9% with 25mg, 7.8% with 75mg and 8.0% with
150mg. The TEAE-related discontinuations were most fre-
quent in patients with LN and RA; in patients with SLE,
there was no difference in discontinuation rates between
atacicept and placebo.
Most common TEAEs (unadjusted for exposure;
DBPC set)
Infections and infestations were the most frequently
reported TEAEs (45.6%), and frequencies were similar be-
tween atacicept 75mg (46.9%), 150mg (49.1%) and pla-
cebo (43.7%), but lower with 25mg (33.3%; Table 3). The
most commonly reported infections and infestations across
all patients were urinary tract infections (10.2%), upper re-
spiratory tract infections (10.1%), and nasopharyngitis
(8.4%; Table 3; Supplementary Table S3, available at
Rheumatology Advances in Practice online). The most fre-
quently reported serious infection was pneumonia (atacicept
75mg, n¼ 9; atacicept 150mg, n¼ 8; and placebo, n¼ 5).
Mortality across the atacicept trial programme
(FA set)
Deaths that occurred across the atacicept clinical trial pro-
gramme are listed in Table 4. Eleven deaths occurred dur-
ing treatment, and exposure-adjusted mortality rates per
100 patient-years (95% CI) were 3.60 (0.90, 14.38), 0.34
(0.05, 2.43) and 1.18 (0.49, 2.82) with atacicept 25, 75 and
150mg, respectively, and 0.44 (0.06, 3.12) with placebo
(Table 5). One of the 11 deaths occurred after administra-
tion of a single dose of 25mg atacicept; this case is de-
scribed in Supplementary Appendix 2, available at
Rheumatology Advances in Practice online. Two additional
patients died after the completion of atacicept treatment:
one patient with RA (9months post-treatment; atacicept
210mg) and one patient with SLE (18months post-
treatment; atacicept 150mg). The exposure-adjusted mor-
tality rate per 100 patient-years (95% CI) in patients with
SLE was 0.78 (0.29, 2.07) across all atacicept-treated
patients and 1.45 (0.54–3.87) with atacicept 150mg; no
Caroline Gordon et al.
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deaths occurred with weight-based atacicept, atacicept
75mg or placebo.
Cardiac events were the most common cause of
death in atacicept-treated patients (n¼4) and were
deemed unrelated or unlikely to be related to treatment
by the investigators.
Infections in SLE patients (SLE set)
Unadjusted rates of serious and/or severe infections
(combined term for analysis) and infestations in
atacicept-treated patients were low and similar between
the APRIL-SLE (19 of 295 patients; 6.4%) and
ADDRESS II studies (including LTE; 13 of 206 patients;
6.3%). An analysis of serious and/or severe infections
by quartile of serum IgG levels and changes in mature
B-cell numbers from baseline showed no association
between pharmacodynamic effects of atacicept and in-
fection rates; these findings were also confirmed across
the full DBPC set. Severe hypogammaglobulinaemia
(IgG <3g/l) occurred in two atacicept-treated patients
with SLE (0.3% of all SLE patients; Supplementary
Table S2, available at Rheumatology Advances in
Practice online) and was not associated with the devel-
opment of infection.
Discussion
We conducted this integrated safety analysis of all 17
atacicept clinical studies to date, including eight DBPC
studies, to characterize the overall safety profile of
atacicept in patients with autoimmune diseases. Similar
to observations with other biologic agents that are fre-
quently used to treat autoimmune diseases [31], the
most commonly observed AEs with atacicept were
infections. This is not unexpected given the proposed
B-cell-targeting mechanism of action of atacicept, which
has been shown to reduce Ig levels and B- and plasma-
cell numbers [13, 14, 22, 25–27]. Our observations are
also consistent with findings from clinical studies of
other BLyS-targeting therapies [32–34]. It should be
noted that although there was an increase in overall in-
fection rates with atacicept compared with placebo, the
rates of serious and severe infections were not higher
with atacicept in patients with SLE, RA or ON.
Furthermore, although infection rates appeared to be in-
creased with atacicept in patients with LN and MS,
these observations should be viewed with caution given
the overall low number of patients studied. Infection
rates in patients with SLE enrolled in the ADDRESS II
study were lower than those in patients enrolled in the
APRIL-SLE study; this could be explained, in part, by
the implementation of risk mitigation measures for
ADDRESS II, following two pulmonary infections with fa-
tal outcome in APRIL-SLE [14]. These mitigation meas-
ures, which included medical monitor reviews of patient
screening data to confirm eligibility and up-to-date vac-
cinations against pneumococcus and seasonal influenza,
have been and continue to be implemented in subse-
quent atacicept studies [15].
Given the immunogenic potential of any biological or
biotechnology-derived protein, hypersensitivity reactions
TABLE 3 Summary of treatment-emergent adverse events 5% in any arm, by dose (double-blind placebo-controlled set)
Placebo
n¼483
Atacicept All subjects
n¼1568
System organ class Preferred
term, n (%)
25 mg
n¼129
75 mg
n¼384
150 mg
n¼572
All doses
n¼1085
Infections and infestations 211 (43.7) 43 (33.3) 180 (46.9) 281 (49.1) 504 (46.5) 715 (45.6)
Urinary tract infection 49 (10.1) 8 (6.2) 46 (12.0) 57 (10.0) 111 (10.2) 160 (10.2)
Upper respiratory tract infection 41 (8.5) 4 (3.1) 41 (10.7) 72 (12.6) 117 (10.8) 158 (10.1)
Nasopharyngitis 33 (6.8) 8 (6.2) 35 (9.1) 55 (9.6) 98 (9.0) 131 (8.4)
Bronchitis 19 (3.9) 4 (3.1) 22 (5.7) 39 (6.8) 65 (6.0) 84 (5.4)
General disorders and administration
site conditions
100 (20.7) 42 (32.6) 145 (37.8) 201 (35.1) 388 (35.8) 488 (31.1)
Injection site reactions 39 (8.1) 24 (18.6) 83 (21.6) 117 (20.5) 224 (20.6) 263 (16.8)
Influenza-like illness 22 (4.6) 15 (11.6) 15 (3.9) 11 (1.9) 41 (3.8) 63 (4.0)
Injection site erythema 3 (0.6) 2 (1.6) 15 (3.9) 29 (5.1) 46 (4.2) 49 (3.1)
Gastrointestinal disorders 97 (20.1) 20 (15.5) 98 (25.5) 129 (22.6) 247 (22.8) 344 (21.9)
Diarrhoea 27 (5.6) 5 (3.9) 27 (7.0) 38 (6.6) 70 (6.5) 97 (6.2)
Nausea 14 (2.9) 8 (6.2) 25 (6.5) 26 (4.5) 59 (5.4) 73 (4.7)
Nervous system disorders 92 (19.0) 28 (21.7) 83 (21.6) 100 (17.5) 211 (19.4) 303 (19.3)
Headache 56 (11.6) 21 (16.3) 56 (14.6) 63 (11.0) 140 (12.9) 196 (12.5)
Musculoskeletal and connective
tissue disorders
86 (17.8) 21 (16.3) 70 (18.2) 105 (18.4) 196 (18.1) 282 (18.0)
Back pain 27 (5.6) 1 (0.8) 24 (6.3) 20 (3.5) 45 (4.1) 72 (4.6)
Respiratory, thoracic and m
ediastinal disorders
50 (10.4) 7 (5.4) 45 (11.7) 66 (11.5) 118 (10.9) 168 (10.7)
Cough 16 (3.3) 2 (1.6) 20 (5.2) 28 (4.9) 50 (4.6) 66 (4.2)
Integrated safety profile of atacicept
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and ISRs were of special interest. As anticipated,
exposure-adjusted hypersensitivity and ISRs were more
frequent with atacicept than placebo. The highest fre-
quencies were in patients treated with atacicept 150mg,
but most reactions were of mild to moderate intensity,
with only a single case of anaphylaxis related to a bee
sting, and no fatal reactions.
Hypogammaglobulinaemia was defined as another AE
of particular interest, based on outcomes of the Phase II/
III DBPC APRIL-LN study (NCT00573157), which was ter-
minated early following an unexpected decline in IgG, to-
gether with several serious infections. However, analysis
suggested that these events might have been attributable
to factors other than atacicept treatment, because the re-
duction in serum IgG levels began 2weeks before ataci-
cept treatment, after the initiation or dose increase of
MMF and CSs [26, 35]. This is consistent with a report
by Broeders et al. [36], which showed that hypogamma-
globulinaemia is common in renal transplant patients who
are treated with MMF and CSs. The analysis of the
pooled DBPC data in this report showed a low incidence
of severe hypogammaglobulinaemia with atacicept (n¼6
patients; 0.4%). Additionally, our analysis of serious and/
or severe infections occurring in patients with SLE en-
rolled in the APRIL-SLE, ADDRESS II and ADDRESS II
LTE studies showed no apparent association between re-
duced serum IgG and mature B-cell levels with serious
and severe infection rates.
Although the incidence of malignancies was numeri-
cally higher with atacicept than with placebo, rates were
overall low and appeared similar to the background rate
of malignancies in SLE patients [37] and to rates
reported with belimumab, based on 7 years of cumula-
tive exposure data in SLE patients [38]. The analysed
sample included considerably more atacicept-treated
than placebo-treated patients, and the imbalance in pa-
tient numbers might therefore account for the numerical
difference in malignancies.
Across all patients (FA set), the number of reported
deaths was 13 (of 1845 patients in total), which is com-
parable to clinical studies of other BLyS- and/or APRIL-
targeting agents [32, 33, 39]. Cardiac events were the
most common cause of death across all atacicept stud-
ies (n¼ 4 of 13 deaths) and were deemed unrelated or
unlikely to be related to treatment. Analyses of the
pooled DBPC data showed that EAIRs of cardiac events
were low overall, with moderate increases for atacicept
vs placebo observed only in patients with MS and RA.
Despite evidence that patients with SLE are at an in-
creased risk of cardiovascular disease [40], EAIRs of
cardiac events observed in this analysis were lower in
patients with SLE than in the other indications and were
similar with atacicept and placebo. Interestingly, BLyS
and APRIL are expressed in human arteriosclerotic pla-
ques, suggesting that they could be a negative prognos-
tic factor in cardiovascular disease [41].
Implications for future studies in SLE patients
Long-term use of standard-of-care treatments for SLE,
including CSs and immunosuppressants, is associated
with adverse effects, including infection [42]; however,
prolonged exposure to these agents is often unavoid-
able owing to the chronic nature of the disease [43].
Thus, there is a need for novel targeted therapies that
not only provide greater efficacy, but also have a safety
profile that is conducive to chronic use.
Although none of the atacicept studies to date has
met its primary endpoint, clinical efficacy was demon-
strated with atacicept 150mg in two large Phase II/III
SLE studies with different study designs (Supplementary
Table S5, available at Rheumatology Advances in
Practice online). In the APRIL-SLE study, atacicept
150mg led to significant treatment benefits, with re-
duced flare rates and delayed time to the first flare over
placebo (post hoc analysis of the discontinued arm) [14],
and Gordon et al. [13] demonstrated that increased ata-
cicept exposure associated with the 150mg dose led to
greater reductions in Ig levels and B-cell numbers (phar-
macodynamic effects), without a significant increase in
hypogammaglobulinemia or infection rates. In the
ADDRESS II study, atacicept 150mg showed significant
treatment benefit over placebo in patients who had HDA
at screening across different efficacy endpoints, and
confirmed the consistent pharmacodynamic effects of
atacicept treatment [15, 28, 44]. Furthermore, no clini-
cally meaningful differences in safety data were ob-
served between the modified intention-to-treat and the
HDA populations in ADDRESS II [15]. Taken together,
these findings support treatment of HDA patients with
SLE with atacicept 150mg in future studies [13–15].
TABLE 5 Exposure-adjusted mortality rates in patients treated with placebo or atacicept 25, 75 or 150mga
Placebo
n¼431
Atacicept 25 mg
n¼130
Atacicept 75 mg
n¼384
Atacicept 150 mg
n¼677
Exposure, patient-years 227.68 55.63 291.66 425.26
Deaths, n 1 2 1 5
Exposure-adjusted
mortality rate, per 100
patient-years (95% CI)
0.44 (0.06, 3.12) 3.60 (0.90, 14.38) 0.34 (0.05, 2.43) 1.18 (0.49, 2.82)
aStudies with single or multiple ascending doses of atacicept (n¼111) and weight-based atacicept (n¼112) were not in-
cluded for this analysis (two deaths occurred in studies of weight-based atacicept).
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The present analysis describes the EAIRs of most
TEAEs in atacicept-treated patients. There was no con-
sistent association with atacicept dose and cardiac
arrhythmias, serious and severe infections, vestibular
disorders, depression or malignant and unspecified
tumours. By clarifying the frequency and severity of the
potential risks associated with atacicept, this analysis
provides a foundation for further investigation of the po-
tential benefits of atacicept in SLE and other serious au-
toimmune diseases, while continuing to implement risk
mitigation measures.
Study limitations
Limitations of this integrated analysis include the differ-
ing designs and patient populations of the studies in-
cluded. In addition, overall patient numbers varied
considerably by disease and dose, and sample sizes
were small in some indications. However, in the DBPC
set, atacicept was investigated in 150–500 patients for
each autoimmune indication (excluding ON and LN) and
130–570 patients for each dose.
Conclusion
In conclusion, the outcomes of this integrated analysis
of safety data from >1800 subjects support further de-
velopment and evaluation of atacicept in selected
patients for whom the potential benefits might outweigh
the risks, with measures to minimize infection-related
risks associated with B-cell-targeting therapies.
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